Related Experiment Video
Updated: Jun 22, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
ErbB targeted drugs and angiogenesis.
Erika Iivanainen1, Klaus Elenius
1Department of Oncology and Radiotherapy, Turku University Central Hospital, FIN-20520 Turku, Finland.
Current Vascular Pharmacology
|June 3, 2009
Summary
ErbB signaling regulates tumor cell functions and angiogenesis. ErbB-targeted cancer drugs, including EGFR inhibitors, show anti-tumor effects partly through inhibiting tumor angiogenesis via poorly understood mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- ErbB receptor tyrosine kinases regulate normal and tumor cell functions.
- Therapeutic inhibitors targeting ErbB signaling (EGFR, ErbB2) are used in various cancers.
- ErbB inhibitors are thought to exert anti-tumor effects by inhibiting tumor angiogenesis.
Purpose of the Study:
- To review the role of ErbB signaling in angiogenesis.
- To discuss the anti-angiogenic mechanisms of ErbB-targeted cancer drugs.
Main Methods:
- Literature review of ErbB signaling in angiogenesis.
- Analysis of proposed anti-angiogenic mechanisms of ErbB inhibitors.
Main Results:
- ErbB signaling plays a key role in tumor angiogenesis.
- ErbB inhibitors impact tumor neovascularization through various mechanisms.
- Several mechanisms by which ErbB inhibitors affect angiogenesis are proposed but not fully characterized.
Conclusions:
- ErbB signaling is a critical target for cancer therapy.
- Understanding the anti-angiogenic effects of ErbB inhibitors is crucial for optimizing cancer treatment.
- Further research is needed to fully elucidate the mechanisms of ErbB-mediated anti-angiogenesis.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...